arrow
M

María José Larráyoz

universidad de navarra and institute for health research (idisna)
H指数:30
被引数:2,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study

NPM1突变急性髓系白血病强化治疗患者中变异等位基因频率的预后影响:PETHEMA研究

Blood
IF23.1
2026-06-100
OAAI
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group

急性髓系白血病患者在首次缓解期接受 allo 移植时分子分型的临床影响:PETHEMA 小组的研究

2026-05-070
PRE
Exploring the synergy between telomere length and genomic complexity in CLL

探索端粒长度与基因组复杂性在CLL中的协同作用

2026-01-230
OAAI
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
2024-08-080
OAAI
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
2024-07-022
OAAI
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

用强化策略治疗的高危阴燃骨髓瘤患者的基因组分析揭示了耐药和进展的潜在标志物

2024-04-290
OAAI
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
2023-05-128
OAAI
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

用于预测遗传异质性多发性骨髓瘤的免疫治疗结果和免疫逃避机制的临床前模型

2023-03-1628
OAAI
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Dec, 10.1038/s41375-022-01802-y, 2022)
LEUKEMIA
IF13.4
2023-01-121
OAAI
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
LEUKEMIA
IF13.4
2022-12-2429
OAAI
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma
2022-01-2123
OAAI
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
2021-10-2016
OAAI
Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients
2021-03-1115
OAAI
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2020-12-1847
OA
Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms
2020-11-2510
OAAI
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
2020-11-1218
OAAI
Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated
2019-01-1722
OAAI
Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia
2018-03-3024
PREAI